| Objective:In this study,Immunochemistry was used to test the expression of GFR?-1 and GFR?-2 and molecular subtypes markers such as ER,PR,HER-2 and Ki-67 in the invasive breast cancer,,and the differences of expression status of these indicators in the primary and recurrent metastatic lesions,respectively,were analyzed.The role of GFR?-1 and GFR?-2 and molecular subtypes markers in breast cancer recurrence,metastasiswill be analyzed,in order to provide a new idea for the individual diagnosis and treatment of breast cancer in the future.Method:A total of 59 patients with invasive breast cancer who were diagnosed and treated at the Affiliated Tumor Hospital of Guangxi Medical University from January 2009 to February 2014 were relapsed and metastasized.The primary tumors and paired recurrent metastatic cancer tissues were collected.The expression of GFR?-1 and GFR?-2 and the molecular markers of breast cancer,including ER,PR,HER-2 and Ki-67 were detected by Immunochemistry in primary and recurrent metastatic cancer tissues,respectively.Statistical software was used to analyze the differences in the expression of the above indicators in primary and recurrent metastatic cancer tissues,to explore the correlation between the expression of related indicators and its relationship with the time of recurrence and metastasis.Results:1.The high expression rate of GFR?-1 in recurrence metastases was higher than that in the primary lesions(?~2=9.465,P=0.002).There was no significant difference in the high expression rate of GFR?-2 and breast cancer molecular markers ER,PR,HER-2 and Ki-67 between primary and recurrent metastases(all P>0.05).2.There was no correlation between the expression of GFR?-1 and GFR?-2 in primary and recurrent metastatic breast cancer(P>0.05).There was no correlation between the expression of GFR?-1 and molecular subtyping(P>0.05).There was a significant correlation between the expression of GFR?-2and the expression of HER-2(P<0.01),but there was no correlation between the expression of ER,PR and Ki-67(P>0.05).3.The median progression-free survival(mDFS)of patients with low GFR?-1 expression was 22.10 months,and the mDFS of high-overexpression group was 21.83 months.There was no significant difference between the two groups(P=0.722).The mDFS was 39.20 months in patients with low expression of GFR?-2,and the median DFS was 19.97 months in patients with high expression,and the difference was statistically significant(P=0.004).The mDFS in the ER low expression group was 14.63 months,and the mDFS in the high expression group was 26.50 months.The difference between the two groups was statistically significant(P=0.000).The mDFS with low PR expression was 15.07 months,and the mDFS in the high expression group was 24.60 months.The difference between the two groups was statistically significant(P=0.009).The mDFS of the HER-2 low expression group was 25.07 months,and the mDFS of the high expression group was 19.30 months.The difference was statistically significant(P=0.002).Of the 29 cases with high expression of HER-2 in primary tumors,only 4 patients received adjuvant anti-HER-2targeting therapy,and there was no significant difference in mDFS between anti-HER-2 and non anti-HER-2 groups(P>0.05).Conclusions:1.In the tissue of recurrence and metastasis of breast cancer,the expression level of GFR?-1 was significantly increased,but the expression status of GFR?-2 and molecular subtyping markers had no significant changes.2.There was no correlation between the expression of GFR?-1 and GFR?-2 in primary and recurrent metastatic lesions of breast cancer.There was no correlation between the expression of GFR?-1 and molecular subtyping markers.The expression of GFR?-2 was significantly correlated with the expression of HER-2,but it was not correlated with the expression of other markers.3.Patients with high expression of GFR?-2,high expression of HER-2(but non anti-HER-2),low expression of ER,and low expression of PR have a higher risk of recurrence and metastasis,with shorter mDFS. |
PDF Full Text Request